U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT06824051) titled 'A Study of Orforglipron (LY3502970) in Adult Participants with Obesity or Overweight' on Jan. 27.
Brief Summary: The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.
Study Start Date: Feb., 2025
Study Type: INTERVENTIONAL
Condition:
Obesity
Overweight
Intervention:
DRUG: Orforglipron
Administered orally
DRUG: Placebo
Administered orally
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Eli Lilly and Company
Disclaimer: Curated by HT Syndication....